Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

An injectable metal-phenolic network hydrogel for coordinated PRP delivery in osteoarthritis treatment.

Created on 21 Nov 2026

Authors

Jing Shi, Tao Wang, Mengyuan Dai, Qinling Liu, Qingxin Fan, Lu Li, Sha Wan, Chen Fan, Yu Wang, Qingquan Kong

Published in

Journal of materials chemistry. B. Nov 20, 2026. Epub Nov 20, 2026.

Abstract

Osteoarthritis (OA) is a prevalent degenerative joint disease for which current therapies remain largely symptomatic. Although platelet-rich plasma (PRP) has shown therapeutic potential in OA, its clinical utility is limited by the rapid release and short retention of bioactive factors after intra-articular administration. In this study, we developed an injectable sodium alginate (SA)-based hydrogel integrated with an epigallocatechin gallate (EGCG)-Zn2+ metal-phenolic network for coordinated PRP delivery. The resulting SM@PRP hydrogel exhibited favorable injectability, multiscale porous architecture, enhanced water retention, reduced degradation rate, and improved antioxidant activity. In vitro release studies demonstrated that the metal-phenolic network delayed the release of multiple PRP-associated growth factors compared with the control hydrogel. Molecular simulation and QCM analyses further supported dynamic interactions between the metal-phenolic network and these growth factors. Biocompatibility assays showed that the hydrogel had minimal cytotoxicity and good hemocompatibility. In IL-1β-stimulated chondrocytes, SM@PRP reduced ROS accumulation and inflammatory mediator levels, while in BMSCs it promoted proliferation and migration. In a rat OA model, intra-articular administration of SM@PRP alleviated cartilage erosion, reduced inflammatory responses, and preserved proteoglycan-rich cartilage matrix during a 14-day observation period. Collectively, these findings suggest that SM@PRP is a promising injectable hydrogel platform for in situ PRP delivery and OA treatment.

PMID:
43063013
Bibliographic data and abstract were imported from PubMed on 21 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement